Global elimination of lymphatic filariasis
| Monday, 3rd of April 2017 |
 |
 |
Summary below; full text is at
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)30544-8/fulltext
The Lancet Infectious Diseases, Volume 17, No. 4, p358–359, April 2017
Comment
Global elimination of lymphatic filariasis
,
Alison P Galvani
Email the author Alison P Galvani
Published: 21 December 2016
Open Access
DOI: http://dx.doi.org/10.1016/S1473-3099(16)30544-8
Lymphatic filariasis is one of the most debilitating neglected tropical diseases, the clinical manifestations of which include painful and incapacitating lymphoedema.1 Among the estimated 68 million people infected, 36 million are microfilaria carriers and 40 million are symptomatic.1Additionally, 946 million people live in areas of southeast Asia and sub-Saharan Africa where mosquito-borne filariasis is endemic and are, therefore, at risk of infection.1 In 2000, WHO launched the Global Programme to Eliminate Lymphatic Filariasis (GPELF), which aims to interrupt transmission of lymphatic filariasis by 2020.
| Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
| Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
| Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
| Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
| Immunization Agenda 2030
Tuesday, 11th of February 2020 |
 |
40921727 |
| www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |